Holen Sie sich die Stockscreener-App
21.00
11.02%
2.085
Handel nachbörslich:
20.83
-0.17
-0.81%
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Spyre Therapeutics Stock Rises 11% After $275 Mln Public Offering Pricing - Nasdaq
Spyre Therapeutics rises after $275 mln equity raise - TradingView
Spyre Therapeutics IncExpects $486.2 million in cash and equivalents as of Sept 30, 2025SEC filing - MarketScreener
Will Spyre Therapeutics Inc. stock recover faster than peersWall Street Watch & Safe Swing Trade Setups - newser.com
Spyre Therapeutics Prices $275 Million Share Offering - MarketScreener
Spyre Therapeutics (NASDAQ:SYRE) Rating Increased to Hold at Wall Street Zen - Defense World
Will Spyre Therapeutics Inc. stock deliver strong dividend growth2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
SYRE Stock Offering Priced Below Recent Closing - GuruFocus
Spyre Therapeutics prices public offering at $18.50 per share - Investing.com
Spyre Therapeutics announces pricing of $275 million public offering of common stock - MarketScreener
$275M Offering — Spyre Therapeutics Prices 14.86M Shares for IBD Biotech - Stock Titan
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock - GlobeNewswire Inc.
Spyre Therapeutics Launches Public Offering - MarketScreener
Spyre Therapeutics announces public offering of common stock and pre-funded warrants - MSN
Spyre Therapeutics announces common stock offering, no amount given - TipRanks
Spyre Therapeutics falls after stock offering launch - TradingView
Spyre Therapeutics announces common stock offering - Investing.com India
Spyre Therapeutics Announces Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Spyre Therapeutics to Offer Common Stock & Pre-Funded Warrants; 30-Day Underwriter Option - Stock Titan
Using Python tools to backtest Spyre Therapeutics Inc. strategiesJuly 2025 Trade Ideas & Real-Time Market Sentiment Alerts - newser.com
Will Spyre Therapeutics Inc. stock pay special dividendsNew Guidance & Accurate Buy Signal Notifications - newser.com
Can Spyre Therapeutics Inc. stock sustain free cash flow growth2025 Major Catalysts & Entry Point Confirmation Signals - newser.com
Why Spyre Therapeutics Inc. stock is a value investor pickQuarterly Trade Review & High Win Rate Trade Tips - newser.com
What sentiment indicators say about Spyre Therapeutics Inc. stockJuly 2025 Momentum & Short-Term Swing Trade Alerts - newser.com
Best data tools to analyze Spyre Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5%Here's Why - MarketBeat
A Fresh Look at Spyre Therapeutics (SYRE) Valuation Following Encouraging SPY002 Clinical Data and Pipeline Advances - Sahm
Analyzing Spyre Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Stock Portfolio Risk Control - newser.com
How to integrate Spyre Therapeutics Inc. into portfolio analysis toolsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Is Spyre Therapeutics Inc. a candidate for recovery playWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Custom strategy builders for tracking Spyre Therapeutics Inc.July 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Spyre Therapeutics' (SYRE) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 8.9%What's Next? - MarketBeat
Should Positive Early IBD Trial Results and Combination Data Prompt Action From Spyre Therapeutics (SYRE) Investors? - Sahm
Spyre Therapeutics (NASDAQ:SYRE) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Published on: 2025-10-06 01:19:10 - newser.com
Spyre Therapeutics (SYRE) Highlights Progress at European Gastro - GuruFocus
Spyre Therapeutics Presents Promising Phase 1 Data for SPY002 at UEGW Congress - Quiver Quantitative
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - The Manila Times
6-Month Data: Spyre's SPY002 Shows Q3M Dosing Potential; Preclinical Combos Superior - Stock Titan
Spyre Therapeutics Inc. stock volume spike explainedWeekly Investment Summary & Real-Time Market Sentiment Reports - newser.com
Tools to monitor Spyre Therapeutics Inc. recovery probability2025 Stock Rankings & Smart Money Movement Tracker - newser.com
Spyre Therapeutics Inc. stock daily chart insightsEarnings Performance Report & Safe Capital Growth Trade Ideas - newser.com
Is Spyre Therapeutics Inc. (3920) stock inflation resilientMarket Risk Analysis & AI Driven Price Predictions - newser.com
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
42,500 Stock Options — Spyre Therapeutics Grants Options at $16.46 to Three Non‑Executive Employees - Stock Titan
What Fibonacci levels say about Spyre Therapeutics Inc. reboundJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
What candlestick patterns are forming on Spyre Therapeutics Inc.Trend Reversal & Weekly High Conviction Ideas - newser.com
Why millennials buy Spyre Therapeutics Inc. (3920) stockTrade Risk Report & Smart Swing Trading Techniques - newser.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $54.29 Average PT from Brokerages - Defense World
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):